Αποτελέσματα Αναζήτησης
27 Ιουλ 2021 · Given the increasing prevalence of diabetes, establishing how diabetes may impact lung cancer risk is important for optimizing lung cancer prevention programs, enhancing screening efforts, and elucidating the pathogenesis of lung cancer histologic subtypes.
- Figure 1
Diabetes is a well-established risk factor for many cancers,...
- Diabetes and Lung Cancer Among Postmenopausal Women
The prevalence of diabetes has been rapidly growing...
- PMC Free Article
INTRODUCTION. Non-small cell lung cancer (NSCLC) is the...
- First Results From a Feasibility Study of The D2C Cohort
Obesity seemed inversely related to cancer risk among...
- Figure 1
22 Ιουλ 2023 · We systematically searched MEDLINE, Embase, Web of Science, and Cochrane CENTRAL from 2011 to March 2021 for studies evaluating associations between diabetes medications and the risk of breast,...
Diabetes is a common comorbidity in patients with early-stage non-small cell lung cancer (NSCLC), a growing population due to increased LC screening. However, it is unknown if diabetes is associated with less aggressive NSCLC treatment and worse NSCLC outcomes.
1 Νοε 2021 · Anti-diabetic drugs for LC. Metformin and thiazolidinediones (TZDs) are two anti-diabetic drugs that have been tested for their anticancer properties and have shown efficacy against LC in preclinical studies [129], [130]. In a mouse model of LC, metformin treatment reduced the tumor burden by 53–72% [131].
20 Μαΐ 2016 · Risk of lung cancer was reduced among users of Thiazolidinediones (TZDs) (SRR = 0.67; 95% CI 0.54, 0.85) but not metformin (SRR = 0.94; 95% CI 0.73, 1.22). Conclusions: The risk of lung cancer is not increased among patients with diabetes compared to non-diabetic subjects.
10 Φεβ 2023 · The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Metab. 2016;5:1048–56.
2 Ιουν 2022 · Background: Lung cancer is the leading cause of cancer death in the United States, with > 85% classified as non-small cell lung cancer (NSCLC). Diabetes mellitus (DM) is a common comorbidity in patients with NSCLC.
